Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Inflammatory Bowel Diseases: full-pipeline trial registry
27 of 49 indexed Inflammatory Bowel Diseases trials are currently recruiting.
Corpus placement: #281 of 28,707 conditions by registered trial count.
49 US clinical trials · 27 currently recruiting · #281 of 28,707 conditions by registered trial count
Inflammatory Bowel Diseases: 49 US clinical trials tracked, 27 recruiting.
Inflammatory Bowel Diseases is the subject of 49 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 4 of these trials.
Enrollment posture brief
Registry condition inflammatory-bowel-diseases
OPEN 27 | RECR 55% | LATE 6 | EARLY 9 | RANK #281 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Diffuse Intrinsic Pontine Glioma (55% recruiting · 29 trials)
Inflammatory Bowel Diseases lists 27 open slots (55% of 49 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Inflammatory Bowel Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Inflammatory Bowel Diseases is recruiting above its size-band peers.
27 of 49 indexed trials (55.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Inflammatory Bowel Diseases trials is spread across many organizations.
Massachusetts General Hospital accounts for 4 of 49 trials (8.2%). 38 distinct sponsors appear on at least one study for this condition label.
-
Typical Inflammatory Bowel Diseases enrolment sits around 96 participants.
Median target enrolment is 96 among the 49 trials that report a genuine target (sentinel values excluded). 25 of those (51%) plan for fewer than 100 participants.
-
Inflammatory Bowel Diseases research is mostly interventional.
36 interventional and 13 observational studies make up this index (73.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
49 total, page 1 of 1
Observational Pharmaco-Epidemiology Research & Analysis
Epividian
NCT03813862
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
University of Chicago
NCT01280825
Registry and Biorepository for IBD in Central Texas
University of Texas at Austin
NCT04617184
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Spyre Therapeutics
NCT07012395
Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease
Montefiore Medical Center
NCT06266663
The Effect of IBD Flares on Serum PSA
Northwestern University
NCT03558048
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
NCT06226883
Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
Seattle Children's Hospital
NCT06315179
Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
NYU Langone Health
NCT06309017
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Eli Lilly and Company
NCT04844606
BOOM-IBD2 Pivotal Clinical Trial
Boomerang Medical
NCT06571669
Heart Rate Variability and Inflammatory Bowel Disease
Emory University
NCT06537258
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Weill Medical College of Cornell University
NCT06274554
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
Children's Hospital Medical Center, Cincinnati
NCT03847467
Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
Massachusetts General Hospital
NCT05332639
IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms
University of Michigan
NCT06094608
Feasibility Test of Action Planning in Pediatric IBD
University of North Carolina, Chapel Hill
NCT06186752
Therapeutic Endpoint in Pediatric IBD Conditions
Children's National Research Institute
NCT06065228
Regulation of Mucosal Healing in Inflammatory Bowel Disease
Terrence A Barrett
NCT04504136
Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients
University of Michigan
NCT06188793
Outpatient VR (Virtual Reality)-Brain-gut Behavioral Therapies (BGBT) in Inflammatory Bowel Disease (IBD)
University of Michigan
NCT06910787
A Study for Imaging the Lower Gastrointestinal Tract Using a Retro-TCE Capsule
Massachusetts General Hospital
NCT07219537
VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems
University of Louisville
NCT03953768
Fermented Food-Supplemented Diet in Ulcerative Colitis
Stanford University
NCT04401605
Beta-Hydroxybutyrate Feasibility Treating IBD
University of Texas at Austin
NCT06351124
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
Stanford University
NCT05912387
Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
Massachusetts General Hospital
NCT07033208
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Target PharmaSolutions
NCT03251118
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
Janssen Biotech
NCT00606346
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
NCT05611671
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
Beth Israel Deaconess Medical Center
NCT04835506
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
University of Maryland, Baltimore
NCT05316584
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
Massachusetts General Hospital
NCT04565821
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development
NCT02407236
Monitoring Serologic Response to Severe Acute Respiratory Syndrome-2 (SARS-COV-2)/COVID-19 in Children
Connecticut Children's Medical Center
NCT04838834
Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions
Duke University
NCT03938324
The Deep South Surgical Equity Research Network: Addressing Socioecological Determinants of Health
University of Alabama at Birmingham
NCT05345054
Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®)
Cedars-Sinai Medical Center
NCT03723447
Cytokines and Genes in Therapeutic Response in Crohn's Disease
Vanderbilt University Medical Center
NCT03266471
Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System
Capso Vision
NCT04573959
Somatosensory Profiles in Individuals With Persistent Musculoskeletal Pain and Inflammatory Bowel Disease
Dartmouth-Hitchcock Medical Center
NCT03799471
Multiple Dose Ethnobridging PK Study in Healthy Subjects
Theravance Biopharma
NCT03750565
A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease
University of Washington
NCT05651542
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
Bristol-Myers Squibb
NCT03254784
SMART-IBD App Trial
Children's Hospital Medical Center, Cincinnati
NCT06023667
Health Coaching as a Tool for Improving Medication Adherence in Adult Patients With Inflammatory Bowel Disease
Vanderbilt University Medical Center
NCT03757533
Examining the Effect of Ondansetron on Bowel Prep Success
State University of New York - Downstate Medical Center
NCT05439772
Digital Behavioral Interventions in Inflammatory Bowel Disease
Montefiore Medical Center
NCT04861597
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
Stacy A. Kahn
NCT02330653
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
| Phase 3 | 3 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Inflammatory Bowel Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Inflammatory Bowel Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Inflammatory Bowel Diseases page
49 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Inflammatory Bowel Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Inflammatory Bowel Diseases trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Inflammatory Bowel Diseases condition card totals 49 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.